Table 1.

Various studies and agents/drugs in the treatment of mCRPC

Study	Drug used	Comparison	Selection criterion	OS in months	PFS	PSA reduction
COU-AA-302 Ryan CJ et al., 2013	Abiraterone + prednisone	Placebo + prednisone	No previous docetaxel ECOG 0-1 PSA or radiographic progression No or mild symptoms No visceral metastases	34.7 versus 30.3	16.5 versus 8.3	>50% in 62%
PREVAIL Beer TM et al., 2014	Enzalutamide	Placebo	No previous docetaxel ECOG 0-1 PSA or radiographic progression No or mild symptoms 10% had visceral metastases	32.4 versus 30.2	20.0 versus 5.4	>50% in 78%
Kantoff PW et al., 2010	Sipuleucel-T	Placebo	Some with previous docetaxel ECOG 0-1 Asymptomatic or minimally symptomatic	25.8 versus 21.7	3.7 versus 3.6	>50% in 26%
Parker et al., 2013	Radium-223	Placebo	Previous or no previous docetaxel ECOG 0-2 Two or more symptomatic bone metastases No visceral metastases	14.9 versus 11.3	NA	>30% in 16%
deBono et al., 2010	Cabazitaxel + prednisone	Mitoxantrone + prednisone	Previous docetaxel ECOG 0-2	15.1 versus 12.7	2.8 versus 1.4	NA
Kratochwil et al.[3]	225Ac-PSMA-617		chemotherapy naïve mCRPC			>50% in 63%

mCRPC=Metastatic castrate resistant prostate cancer, PSA=Prostate-specific antigen, OS=Overall survival, PSMA=Prostate-specific membrane antigen, NA=Not available, ECOG=Eastern Cooperative Oncology Group